Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bot Image

- PMLiVE

AI-supported mammography screening shows promise in breast cancer detection

The AI-supported screening tool detected cancer in 244 people in the study

AI in healthcare communication, today and tomorrow.

Advances in AI technology have meant that agencies can now provide genuine utility to healthcare communications.

Page & Page and Partners

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

How Pharma, Payers, & Providers are Leveraging Patient Self-Management Platforms

Rick Anderson, President of DarioHealth, explores digital therapeutics, how DarioHealth is utilizing #ai and behavioral science to personalize each user’s health journey, and how this approach can help improve #diversity...

Impetus Digital

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

NICE announces launch of digital and AI advice service for healthcare sector

Four UK healthcare organisations collaborated on the AI and Digital Regulations Service

Train your brain for success

In this episode of Impetus Digital‘s Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital sits down with Max Newlon, President of Brain Co. They discuss everything from...

Impetus Digital

- PMLiVE

AI model shows promise in detecting lung cancer earlier

Lung cancer accounts for more than 20% of cancer deaths in the UK

ChatGPT AI copywriter: Looming threat or opportunity to evolve?

Even as someone who makes a living working in healthcare communications, I can still spend many hours copywriting without much progress – it is the nature of the beast [come...

Page & Page and Partners

- PMLiVE

Janssen’s Akeega receives EC approval for metastatic prostate cancer

The authorisation marks the first worldwide approval of the niraparib-based combination

- PMLiVE

Moderna and IBM to explore quantum computing and AI for future mRNA medicines

A growing number of biopharmas have been investing in quantum computing over recent years

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links